Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.

PubWeight™: 12.82‹?› | Rank: Top 0.1% | All-Time Top 10000

🔗 View Article (PMC 2996043)

Published in Lancet on July 16, 2010

Authors

Julio S G Montaner1, Viviane D Lima, Rolando Barrios, Benita Yip, Evan Wood, Thomas Kerr, Kate Shannon, P Richard Harrigan, Robert S Hogg, Patricia Daly, Perry Kendall

Author Affiliations

1: British Columbia Centre for Excellence in HIV/AIDS, Providence Health Care, Vancouver, BC, Canada. jmontaner@cfenet.ubc.ca

Articles citing this

(truncated to the top 100)

Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84

High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science (2013) 8.24

Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med (2012) 7.04

Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One (2013) 5.01

The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study. Lancet Infect Dis (2013) 3.59

Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44

HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS (2011) 3.39

HIV incidence in men who have sex with men in England and Wales 2001-10: a nationwide population study. Lancet Infect Dis (2013) 3.10

Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med (2011) 2.76

Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One (2013) 2.55

Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res (2011) 2.45

Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet (2013) 2.31

HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention. PLoS Med (2012) 2.21

The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis (2011) 2.20

Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. PLoS One (2014) 2.20

U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18

Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS (2013) 2.17

Antiretroviral therapy for the prevention of HIV transmission: what will it take? Clin Infect Dis (2014) 2.14

HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS (2012) 1.97

Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings? Clin Infect Dis (2013) 1.92

The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: towards elimination of HIV transmission. J Acquir Immune Defic Syndr (2013) 1.85

Population-based metrics for the timing of HIV diagnosis, engagement in HIV care, and virologic suppression. AIDS (2012) 1.76

The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon? J Health Care Poor Underserved (2013) 1.75

Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73

Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study. PLoS Med (2013) 1.73

Consideration of postpartum management in HIV-positive Haitian women: an analysis of CD4 decline, mortality, and follow-up after delivery. J Acquir Immune Defic Syndr (2012) 1.62

HIV treatment as prevention: models, data, and questions--towards evidence-based decision-making. PLoS Med (2012) 1.62

Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev (2013) 1.56

The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa. AIDS (2012) 1.55

HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med (2012) 1.55

Antiretrovirals and safer conception for HIV-serodiscordant couples. Curr Opin HIV AIDS (2012) 1.51

Missed opportunities for HIV testing and late-stage diagnosis among HIV-infected patients in Uganda. PLoS One (2011) 1.50

Simplified HIV Testing and Treatment in China: Analysis of Mortality Rates Before and After a Structural Intervention. PLoS Med (2015) 1.50

Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS (2013) 1.49

Human leukocyte antigen (HLA) class I down-regulation by human immunodeficiency virus type 1 negative factor (HIV-1 Nef): what might we learn from natural sequence variants? Viruses (2012) 1.48

Community viral load, antiretroviral therapy coverage, and HIV incidence in India: a cross-sectional, comparative study. Lancet HIV (2016) 1.47

Community viral load as a measure for assessment of HIV treatment as prevention. Lancet Infect Dis (2013) 1.43

Disparities in the burden of HIV/AIDS in Canada. PLoS One (2012) 1.42

A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs. Curr HIV/AIDS Rep (2012) 1.37

Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS One (2012) 1.37

Combination prevention: new hope for stopping the epidemic. Curr HIV/AIDS Rep (2013) 1.36

Beyond the distinction between biomedical and social dimensions of HIV prevention through the lens of a social public health. Am J Public Health (2012) 1.34

Shifting the paradigm: using HIV surveillance data as a foundation for improving HIV care and preventing HIV infection. Milbank Q (2013) 1.33

Trends in detectable viral load by calendar year in the Australian HIV observational database. J Int AIDS Soc (2011) 1.31

HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions. PLoS Med (2012) 1.29

Measuring population transmission risk for HIV: an alternative metric of exposure risk in men who have sex with men (MSM) in the US. PLoS One (2012) 1.28

Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis (2012) 1.26

Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia. J Acquir Immune Defic Syndr (2013) 1.23

Tracking the evolution of HIV/AIDS in China from 1989-2009 to inform future prevention and control efforts. PLoS One (2011) 1.22

Estimating the HIV incidence rate: recent and future developments. Curr Opin HIV AIDS (2011) 1.21

Does ART prevent HIV transmission among MSM? AIDS (2012) 1.20

Advanced disease at enrollment in HIV care in four sub-Saharan African countries: change from 2006 to 2011 and multilevel predictors in 2011. AIDS (2014) 1.17

Addressing the Achilles' heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation. Clin Infect Dis (2014) 1.17

Rates and correlates of antiretroviral therapy use and virologic suppression among perinatally and behaviorally HIV-infected youth linked to care in the United States. J Acquir Immune Defic Syndr (2015) 1.12

Effective HIV prevention: the indispensable role of social science. J Int AIDS Soc (2012) 1.12

Antiretroviral therapy: a promising HIV prevention strategy? J Acquir Immune Defic Syndr (2010) 1.11

Community viral load and CD4 count distribution among people living with HIV in a South African Township: implications for treatment as prevention. J Acquir Immune Defic Syndr (2013) 1.11

Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. AIDS (2013) 1.10

HIV-1 Genetic Variability and Clinical Implications. ISRN Microbiol (2013) 1.10

A community-based study of barriers to HIV care initiation. AIDS Patient Care STDS (2011) 1.10

A complex systems approach to evaluate HIV prevention in metropolitan areas: preliminary implications for combination intervention strategies. PLoS One (2012) 1.09

Application and validation of case-finding algorithms for identifying individuals with human immunodeficiency virus from administrative data in British Columbia, Canada. PLoS One (2013) 1.09

Prospects of elimination of HIV with test-and-treat strategy. Proc Natl Acad Sci U S A (2013) 1.08

Development and validation of a composite programmatic assessment tool for HIV therapy. PLoS One (2012) 1.06

Attrition through multiple stages of pre-treatment and ART HIV care in South Africa. PLoS One (2014) 1.06

Antiretroviral therapy reduces HIV transmission in discordant couples in rural Yunnan, China. PLoS One (2013) 1.05

HIV treatment as prevention: the key to an AIDS-free generation. J Food Drug Anal (2013) 1.05

Late HIV diagnosis: Differences by rural/urban residence, Florida, 2007-2011. AIDS Patient Care STDS (2014) 1.05

Psychiatric correlates of HAART utilization and viral load among HIV-positive impoverished persons. AIDS (2011) 1.05

Home-based HIV counseling and testing: client experiences and perceptions in Eastern Uganda. BMC Public Health (2012) 1.04

Health care and HIV testing experiences among Black men in the South: implications for "Seek, Test, Treat, and Retain" HIV prevention strategies. AIDS Patient Care STDS (2012) 1.04

Responding to the National HIV/AIDS Strategy-setting the research agenda. J Acquir Immune Defic Syndr (2011) 1.02

Trends in AIDS Deaths, New Infections and ART Coverage in the Top 30 Countries with the Highest AIDS Mortality Burden; 1990-2013. PLoS One (2015) 1.02

Use of antiretroviral therapy in households and risk of HIV acquisition in rural KwaZulu-Natal, South Africa, 2004–12: a prospective cohort study. Lancet Glob Health (2014) 1.01

Availability of HIV prevention and treatment services for people who inject drugs: findings from 21 countries. Harm Reduct J (2013) 1.00

Clinician practices and attitudes regarding early antiretroviral therapy in the United States. J Acquir Immune Defic Syndr (2012) 0.99

Improvements in HIV care engagement and viral load suppression following enrollment in a comprehensive HIV care coordination program. Clin Infect Dis (2014) 0.99

Modelling the impact of antiretroviral therapy on the epidemic of HIV. Curr HIV Res (2011) 0.98

Understanding the disparity: predictors of virologic failure in women using highly active antiretroviral therapy vary by race and/or ethnicity. J Acquir Immune Defic Syndr (2013) 0.96

Rising population cost for treating people living with HIV in the UK, 1997-2013. PLoS One (2010) 0.96

Process monitoring of an HIV treatment as prevention program in British Columbia, Canada. J Acquir Immune Defic Syndr (2014) 0.96

Qualitative Assessment of Barriers and Facilitators of Access to HIV Testing Among Men Who Have Sex with Men in China. AIDS Patient Care STDS (2015) 0.95

Cost-effectiveness of antiretroviral therapy for prevention. Curr HIV Res (2011) 0.95

Willingness to use the oral fluid HIV rapid test among men who have sex with men in Beijing, China. PLoS One (2013) 0.94

A typology of structural approaches to HIV prevention: a commentary on Roberts and Matthews. Soc Sci Med (2012) 0.94

HIV treatment for prevention. J Int AIDS Soc (2011) 0.93

Cohort profile: Seek and treat for the optimal prevention of HIV/AIDS in British Columbia (STOP HIV/AIDS BC). Int J Epidemiol (2014) 0.93

Tracking linkage to HIV care for former prisoners: a public health priority. Virulence (2012) 0.93

Incarceration is associated with used syringe lending among active injection drug users with detectable plasma HIV-1 RNA: a longitudinal analysis. BMC Infect Dis (2013) 0.93

Aggregate versus day level association between methamphetamine use and HIV medication non-adherence among gay and bisexual men. AIDS Behav (2013) 0.92

Sex-Based Differences in Rates, Causes, and Predictors of Death Among Injection Drug Users in Vancouver, Canada. Am J Epidemiol (2016) 0.92

people who inject drugs, HIV risk, and HIV testing uptake in sub-Saharan Africa. J Assoc Nurses AIDS Care (2012) 0.92

Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011. BMC Infect Dis (2014) 0.92

Morbidity and risk of subsequent diagnosis of HIV: a population based case control study identifying indicator diseases for HIV infection. PLoS One (2012) 0.91

Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs. J Infect Dis (2013) 0.91

Discussions of viral load in negotiating sexual episodes with primary and casual partners among men who have sex with men. AIDS Care (2012) 0.91

Conduct disorder and adult psychiatric diagnoses: associations and gender differences in the U.S. adult population. J Psychiatr Res (2011) 0.91

Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic. PLoS Genet (2014) 0.91

Depression during pregnancy and the postpartum among HIV-infected women on antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr (2014) 0.90

Articles cited by this

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18

Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01

Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79

Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ (1987) 27.11

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet (2008) 12.35

Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS (2009) 11.62

Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA (2000) 10.17

Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet (2008) 7.42

The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17

Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14

The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08

Integrating HIV prevention and treatment: from slogans to impact. PLoS Med (2005) 6.73

Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03

Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses (2001) 6.00

A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science (2000) 5.52

Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis (2004) 4.17

Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis (2002) 3.58

Prevalence and structural correlates of gender based violence among a prospective cohort of female sex workers. BMJ (2009) 3.56

Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS (1997) 3.42

Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38

Coming to terms with complexity: a call to action for HIV prevention. Lancet (2008) 3.15

Decline in deaths from AIDS due to new antiretrovirals. Lancet (1997) 3.13

Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis (2010) 3.12

Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS (2009) 2.77

Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS (2000) 2.61

Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa. Lancet (2000) 2.42

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. AIDS (2008) 2.27

Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science (2010) 2.19

Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 2.11

Enhanced HIV testing, treatment, and support for HIV-infected substance users. JAMA (2010) 1.67

Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. PLoS One (2010) 1.65

Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma. HIV Med (2009) 1.51

Childhood trauma and injection drug use among high-risk youth. J Adolesc Health (2009) 1.33

Determinants of cutaneous injection-related infection care at a supervised injecting facility. Ann Epidemiol (2009) 1.14

Articles by these authors

Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61

The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17

Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03

Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS (2003) 5.53

Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS (2002) 5.21

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med (2002) 4.77

Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med (2011) 4.68

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis (2004) 4.55

The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ (2011) 4.54

Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med (2003) 4.46

Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ (2003) 4.38

Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24

Social and structural violence and power relations in mitigating HIV risk of drug-using women in survival sex work. Soc Sci Med (2007) 4.14

Structural and environmental barriers to condom use negotiation with clients among female sex workers: implications for HIV-prevention strategies and policy. Am J Public Health (2009) 3.85

Safer injection facility use and syringe sharing in injection drug users. Lancet (2005) 3.85

Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72

Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ (2002) 3.70

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS (2006) 3.70

The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (2009) 3.67

Changes in Canadian heroin supply coinciding with the Australian heroin shortage. Addiction (2006) 3.65

Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct J (2006) 3.49

Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46

Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38

Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr (2006) 3.38

Rationale for evaluating North America's first medically supervised safer-injecting facility. Lancet Infect Dis (2004) 3.20

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ (2003) 3.19

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17

Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet (2011) 3.14

Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis (2010) 3.12

The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Int J Drug Policy (2008) 3.05

Estimated numbers of men and women infected with HIV/AIDS in Tijuana, Mexico. J Urban Health (2006) 3.04

Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS (2007) 3.04

Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med (2008) 2.97

Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog (2007) 2.81

Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78

Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA (2008) 2.77

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76

Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS (2002) 2.74

Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74

Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr (2005) 2.74

Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction (2010) 2.65

Displacement of Canada's largest public illicit drug market in response to a police crackdown. CMAJ (2004) 2.63

Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ (2004) 2.62

A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis (2006) 2.61

Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis (2011) 2.60

Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis (2011) 2.55

Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS (2009) 2.55

Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend (2006) 2.53

Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. CMAJ (2009) 2.51

Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther (2007) 2.49

When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis (2005) 2.48

Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis (2005) 2.42

N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med (2007) 2.41

The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS (2007) 2.39

The impact of a police presence on access to needle exchange programs. J Acquir Immune Defic Syndr (2003) 2.37

Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend (2006) 2.33

Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol (2008) 2.32

The association between food insecurity and mortality among HIV-infected individuals on HAART. J Acquir Immune Defic Syndr (2009) 2.31